PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age

FDA News, New FDA Approvals
June 7, 2019
A+ A-
Email Print

Article Link: PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age

SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental New Drug Application (sNDA) for Emflaza (deflazacort)…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post